Literature DB >> 12941931

Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.

Virginie Perrin1, Fabrizio Mammano.   

Abstract

We investigated the parameters driving nelfinavir resistance, along the D30N and L90M evolutionary pathways. The advantage of the D30N mutant was mostly due to its resistance level, while the L90M mutation allowed preservation of infectivity coupled with minimal resistance. Emergence of secondary mutations further increased the selective advantage of viruses harboring D30N.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12941931      PMCID： PMC224578          DOI： 10.1128/jvi.77.18.10172-10175.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  11 in total

1.  The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance.

Authors:  M Vaillancourt; D Irlbeck; T Smith; R W Coombs; R Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  1999-03-01       Impact factor: 2.205

Review 2.  HIV drug resistance and viral fitness.

Authors:  F Clavel; E Race; F Mammano
Journal:  Adv Pharmacol       Date:  2000

Review 3.  Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors.

Authors:  N A Roberts
Journal:  AIDS       Date:  1995-12       Impact factor: 4.177

4.  Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.

Authors:  F Mammano; V Trouplin; V Zennou; F Clavel
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

Authors:  J Martinez-Picado; A V Savara; L Sutton; R T D'Aquila
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

7.  Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Wataru Sugiura; Zene Matsuda; Yoshiyuki Yokomaku; Kurt Hertogs; Brendan Larder; Tsuyoshi Oishi; Aiko Okano; Teiichirou Shiino; Masashi Tatsumi; Masakazu Matsuda; Hanae Abumi; Noboru Takata; Satoshi Shirahata; Kaneo Yamada; Hiroshi Yoshikura; Yoshiyuki Nagai
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.

Authors:  Wolfgang Resch; Rainer Ziermann; Neil Parkin; Andrea Gamarnik; Ronald Swanstrom
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.

Authors:  F Mammano; C Petit; F Clavel
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

Authors:  A K Patick; M Duran; Y Cao; D Shugarts; M R Keller; E Mazabel; M Knowles; S Chapman; D R Kuritzkes; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
View more
  12 in total

1.  Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs.

Authors:  Nick C T Schopman; Anja Braun; Ben Berkhout
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.

Authors:  Romina Quercia; Elisabeth Dam; Danielle Perez-Bercoff; François Clavel
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

3.  The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.

Authors:  J Wang; H Liang; L Bacheler; H Wu; K Deriziotis; L M Demeter; C Dykes
Journal:  Virology       Date:  2010-04-18       Impact factor: 3.616

4.  Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.

Authors:  S Weinheimer; L Discotto; J Friborg; H Yang; R Colonno
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.

Authors:  Carrie Dykes; Hulin Wu; Matthew Sims; Jeanne Holden-Wiltse; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2010-09-08       Impact factor: 5.948

6.  Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.

Authors:  Manabu Aoki; David J Venzon; Yasuhiro Koh; Hiromi Aoki-Ogata; Toshikazu Miyakawa; Kazuhisa Yoshimura; Kenji Maeda; Hiroaki Mitsuya
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 7.  HIV resistance to raltegravir.

Authors:  Francois Clavel
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

8.  Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.

Authors:  Luis M F Gonzalez; Rodrigo M Brindeiro; Renato S Aguiar; Helena S Pereira; Celina M Abreu; Marcelo A Soares; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

Authors:  Xiaoqing Liu; Zhilong Xiu; Ce Hao
Journal:  J Comput Aided Mol Des       Date:  2009-02-15       Impact factor: 3.686

Review 10.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.